About a quarter of patients with primary localised soft tissue sarcoma (STS) die within the first 5 years of being diagnosed ([@bib23]). Risk stratification is difficult and adjuvant treatment is toxic and has low efficacy. Novel prognostic and predictive markers are needed to make informed decisions and guide individualised treatment ([@bib18]).

Hypoxia is an adverse prognostic factor in different malignancies ([@bib16]; [@bib12]; [@bib13]; [@bib26]; [@bib5]) and its role in sarcoma has recently been explored ([@bib20]). There is experimental evidence implicating hypoxia in increasing metastatic potential and dissemination of sarcomas ([@bib9]; [@bib21]; [@bib10]). Traditionally, the Eppendorf needle electrode has been used for measuring tumour hypoxia. These measurements have shown that the level of pretreatment tumour oxygenation is a prognostic marker for disease-specific survival in STS patients ([@bib25]), and that preoperative low tumour pO~2~ could be an indicator of aggressive disease ([@bib4]). However, the Eppendorf method is invasive and requires special equipment and expertise.

An alternative way to determine tumour hypoxia is to monitor the expression of certain hypoxia-induced genes, whose change in expression is important for cellular adaptation to an anaerobic environment. This is a non-invasive and rapid method to reveal the presence of hypoxia in STS viable tumour tissue. If the hypoxia-induce gene profile is of prognostic value, it may help stratify patients for treatment either with more aggressive modalities or with hypoxia-targeting drugs.

The hypoxia-induced gene profile investigated in this paper was developed as a predictive marker for hypoxic modification of radiotherapy in head and neck cancer ([@bib34]) and includes genes that are upregulated by hypoxia in a pH-independent manner ([@bib32]).

The aim of the present study was to investigate the prognostic role of this hypoxia-induced gene profile in STS patients.

Materials and methods
=====================

Patient cohorts
---------------

The study was performed on a test cohort of 55 patients and validated in an independent cohort of 77 patients.

The test cohort was built around the original material of 42 STS patients investigated by [@bib25] and by [@bib2] in which hypoxia was measured using Eppendorf method between 1993 and 2001. Four patients were excluded because of benign histology and 8 patients because ofto lack of available tissue samples. The remaining 30 patients were matched 1 : 2 to the Aarhus Sarcoma Registry (ASR), a recently validated comprehensive clinical population-based database ([@bib22]).

The matching was done based on histological type, age at diagnosis, sex, and year of diagnosis. Exact match was not possible, but the cases that were 'best possible matches\', according to the above-mentioned order of criteria, were manually selected. Inclusion was restricted to high-grade, localised STS with stored formalin-fixed, paraffin-embedded (FFPE) tissue samples taken before any treatment and with sufficient tissue for high-quality mRNA analysis. This resulted in a test cohort of 55 patients. For inclusion and exclusion criteria, see [Figure 1](#fig1){ref-type="fig"}.

The validation cohort was chosen among all patients treated with curatively intended surgery and postoperative radiation therapy for localised STS between 1998 and 2008. Patients without pretreatment FFPE tissue samples, as well as tissue samples with insufficient mRNA quality were excluded. This resulted in a cohort of 77 patients. Power calculation for the validation cohort was based on an expected hazard ratio (HR) of 2.0 between the more hypoxic and the less hypoxic patient groups. Based on this calculation, 66 patients were needed to detect this difference with 80% power.

The median follow-up time was 5.5 years (0.2--23.8) and for patients still alive the median follow-up time was 8.2 years (4.4--23.8).

Tissue samples and preparation
------------------------------

FFPE tissue samples taken at the time of biopsy or surgery were used for investigation of the hypoxia-induced genes. These tissue samples represented different histological types: undifferentiated pleomorphic sarcoma (UPS; *n*=51), liposarcoma (*n*=28), leiomyosarcoma (*n*=16), synovial sarcoma (*n*=14), malignant peripheral nerve sheath tumour (*n*=8), fibrosarcoma (*n*=7), extra osseous osteosarcoma (*n*=3), rhabdomyosarcoma (*n*=3), and extra-osseous Ewing/PNET (*n*=2). Information about time from tissue collection to fixation and fixation times was not available. Samples were excluded if haematoxylin and eosin (HE) staining showed either \>90% necrotic or 100% normal tissue. A specialised sarcoma pathologist reviewed all HE staining for estimation of the degree of necrosis.

Total RNA was extracted from 7-μm whole FFPE tissue sections by the Tissue Preparation System with VERSANT Tissue Preparation Reagents (Siemens Healthcare Diagnostics, Tarrytown, NY, USA), a fully automated, bead-based RNA isolation method as described elsewhere ([@bib3]). DNase I treatment was applied to remove any potential genomic DNA before cDNA preparation. Purified mRNA from FFPE tissue samples is known to be highly degraded and the mRNA quantity was therefore not determined. Yet, to perform RT-qPCR on the partly degraded RNA, short amplicons and pre-amplification steps were used as described and validated previously ([@bib36]; [@bib30]).

Primers and RT-qRCR
-------------------

The cDNA preparation was performed using the high-capacity cDNA Archive kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer\'s protocol. First 10 cycles of pre-amplification were completed with few modification of the manufacturer\'s protocol (Taqman Preamp Master Mix, Applied Biosystems) as described elsewhere ([@bib30]). The reference genes originally selected for the gene profile were chosen because of the high-correlation coefficient (*ρ*=0.98, *P*\<0.001) between these genes and the 3 most stable reference genes previously tested among 22 well-known reference genes in 22 sarcoma patients representing part of the test ([@bib1]). All genes included in the analysis were upregulated by hypoxia in different tumour models and comprised a hypoxia-induced gene profile developed as a predictive factor in head and neck cancer (see [Supplementary Table I](#sup1){ref-type="supplementary-material"}, for genes and assay identification; [@bib34]), patent no. WO/2012/146259. Assays were selected with an exon junction spanning probe when available. RT-qPCR was performed on an ABI PRISM 7900HT (Applied Biosystem) in 384-well plates by a Biomek 3000 (Beckman Coulter Inc., Brea, CA, USA). The final mixtures consisted of 3 *μ*l pre-amplified cDNA plus 2 × TaqMan Genotyping Master Mix (Applied Biosystems) and 1 × TaqMan assay including primers and probes at a final volume of 15 *μ*l. The experiment was initiated by one cycle at 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s, and 60 °C for 1 min. All tissue samples were run in duplicates.

Data analysis and statistics
----------------------------

The thresholds of the RT-qPCR analysis were set in the SDS2.1 software (Applied Biosystems). All quantitation cycle (Cq)-values with a s.d.\>0.3 were excluded from further analysis; and if s.d. was \>0.3 for one of the reference genes, the entire sample was excluded. ΔCq-values were generated by normalising the Cq-values using the geometric mean of the reference genes. The tissue samples of the test cohort were sorted according to the median rank of the gene expression levels for the 15 genes included in the profile. The gene expression for each investigated gene was ranked under the assumption that a high expression was caused by hypoxia. Although [@bib36] divided the patients into more hypoxic and less hypoxic groups based on the oxygen tension measurement, we have done this division according to the expression of the genes in the test cohort. Individual samples were classified by calculating the distance (*D*) between the ΔCq-values obtained in individual samples and the median ΔCq-values of the test cohort in a manner similar to what was previously described by [@bib36]. Allocation into a more or a less hypoxic group was determined by the highest B/W ratio in the test cohort. The B/W ratio is defined as the variation between groups divided by the variation within a group. The cut-points for the individual genes obtained in the test cohort were applied to the validation cohort to allocate patients into the more or the less hypoxic group, independent of the patient outcome.

The primary end point was disease-specific mortality, timed from the date of sarcoma diagnosis until death with sarcoma as death from other causes was regarded as a competing event. Secondary end points were as follows: overall mortality, timed from the date of sarcoma diagnosis until death from any cause, and development of metastatic disease, defined as metastasis with no possibility of curative treatment, timed from the date of primary sarcoma diagnosis until diagnosis of metastatic disease. The study ended on 15 April 2013. Patients alive at this date were censored. Differences in patients characteristics were tested using *χ*^2^-test, Fishers exact test, or Wilcoxon rank test. The cumulative incidence function was reported for disease-specific mortality or as overall mortality using the Fine and Gray model. Crude and adjusted estimates were reported with 95% confidence interval (CI) using the Cox proportional hazard model. The assumptions for the individual model were tested and no violations were observed. Adjustments were made for potential confounders affecting the association between the gene expression and the outcome. The confounders included were as follows: age at diagnosis (continuous), primary tumour size (continuous), comorbidity (yes *vs* no), site (axial/pelvis/head *vs* extremities), histological type (liposarcoma *vs* UPS *vs* synovial sarcoma *vs* others), and surgical margin (wide *vs* intralesional/marginal). The choice of potential confounders was based on literature review. In the multivariate analysis, 12 patients with grade 2 tumours, 6 patients with superficial tumours, and 4 patients who received chemotherapy were excluded. The model including the hypoxia-induced gene profile was tested against the model without the profile using likelihood-ratio test. The robustness of the final model including the hypoxia-induced gene profile was tested using the bootstrapping method with 1000 iterations.

Heat maps visualising the gene expression levels were generated by Genesis release 1.7.6 ([@bib33]) using the median centred data. The correlation between different tissue blocks from the same patient was tested by concordance correlation coefficient (Rho_c). A two-sided *P* value \<0.05 was regarded as significant. All statistical analyses were performed by using Stata version 14 (Metrika Consulting AB, Västervik, Sweden).

Ethics
------

The Ethics Committee of Denmark (no 1-10-72-233-12) and the Danish Agency of Data Protection (no 2012-41-0657) have approved the study.

Results
=======

Test and validation cohorts
---------------------------

Patient, tumour and treatment characteristics for the test, and validation cohorts are shown in [Table 1](#tbl1){ref-type="table"}. There were statistically significant differences between the test and validation cohorts regarding the number of patients treated with postoperative radiation therapy, tumour grade, tumour depth, and margin after primary surgery.

The robustness of the gene expression in different tissue samples (different pathological blocks) from the same patient were tested in 15 patients. The strong correlation was manifested by a concordance correlation coefficient value of 0.88 (95% CI: 0.85; 0.91). For the concordance of all the genes in the profile and each individual gene see [Supplementary Document II](#sup1){ref-type="supplementary-material"} ([Supplementary Figure IIA and IIC](#sup1){ref-type="supplementary-material"}). In 13 patients, the analysis of both tissue samples (blocks) lead to the same hypoxia classification, whereas in 2 patients, the classification was different between the blocks. For 16 patients, corresponding oxygen tension measurements and expression of the hypoxia-induced gene profile were present. A reverse association between the oxygen tension measurement and the gene expression was found as shown in [Table 2](#tbl2){ref-type="table"}. The Spearman\'s *ρ* coefficient was indicating a weak correlation of −0.45 (*P*=0.04) between pO~2~ measurements and tumour size. The larger the tumour, the lower was the oxygen tension measurements ([Supplementary Figure IIB](#sup1){ref-type="supplementary-material"}).

Survival analysis
-----------------

The expression of the genes expressions of the test cohort in the more and the less hypoxic tumours are illustrated in the heat maps ([Figure 2A](#fig2){ref-type="fig"}). [Figure 2B](#fig2){ref-type="fig"} shows the disease-specific mortality and [Figure 2C](#fig2){ref-type="fig"} the overall mortality in the test cohort for the more and the less hypoxic groups of patients. In the test cohort, the HR for patients with a high expression of the gene profile (the more hypoxic group) was 4.09 (95% CI: 1.34; 12.46), *P*=0.013, compared with patients with a low expression of the gene profile regarding disease-specific mortality. The number of patients who experienced recurrent disease was higher in the more hypoxic, compared with the less hypoxic group; odds ratio of 3.96 (95% CI: 0.98; 14.7), *P*=0.03.

Seventy-seven patients with localised grade 2 or 3 STS treated with surgical resection and postoperative radiation therapy (but no chemotherapy) were divided into a more hypoxic and a less hypoxic groups. The gene expression values used to set the cut-point of each gene in the test cohort were applied to the validation cohort. Of these 77 patients, 30 (39%) were allocated to the more hypoxic group and 47 (61%) were allocated to the less hypoxic group. Interestingly, all patients with synovial sarcoma were allocated to the less hypoxic group. [Figure 2D](#fig2){ref-type="fig"} shows the heat map of the gene expression in the validation cohort. Both the disease-specific mortality ([Figure 2E](#fig2){ref-type="fig"}) and overall mortality ([Figure 2F](#fig2){ref-type="fig"}) were significantly higher in patients with more hypoxic tumours in the validation cohort. The HR was 2.03 (95% CI: 1.02; 4.04) *P*=0.045 for disease-specific mortality and 2.01 (95% CI: 1.11; 3.64) *P*=0.02 for overall mortality. In the validation cohort, 16 out of 30 (53%) of patients in the more hypoxic group developed recurrent/metastatic disease compared with 23 out of 47 (49%) of patients in the less hypoxic group.

Disease-specific mortality and overall mortality in the pooled data
-------------------------------------------------------------------

Pooled analysis of the test and validation cohorts after exclusion of grade 2 tumours, superficial tumours, and patients treated with additional chemotherapy were done. The selection was done to eliminate confounding by grade and superficial location, as only a few patients had these characteristics. Patients, tumour, and treatment-related characteristics are shown in [Table 3](#tbl3){ref-type="table"}. The results confirmed the prognostic value of the hypoxia-induced gene profile. Patients with high expression of the gene profile had significantly higher cumulative incidence of death from sarcoma compared with patients with low expression. The model including the hypoxia-induced gene profile was significantly better in a likelihood-ratio test (*P*=0.0019) than the model without the hypoxia-induced gene profile. Both univariate and multivariate analyses were performed and are shown in [Table 4](#tbl4){ref-type="table"}. The adjusted HR for the development of metastatic disease was 2.61 (1.27; 5.33) *P*=0.009 for patients with more hypoxic tumours compared with the less hypoxic tumours. Using bootstrapping, the HR was 3.18 (95% CI: 1.0; 9.8) *P*=0.044.

Discussion
==========

The hypoxia-induced gene profile investigated in this paper was developed in head and neck cancer ([@bib34]), but recent *in vitro* data have demonstrated a potential in other cancer types ([@bib31]). This study demonstrated that the expression of the hypoxia-induced gene profile tested in pretreatment FFPE tissue is a prognostic factor for STS patients.

The unique composition of genes presented here takes into account different mechanisms by which hypoxia affects tumour biology and the collective effect of these genes has not been described in sarcomas before. The hypoxia-induced gene profile includes genes such as *LOX*, *P4HA1*, and *P4HA2* that are involved in extracellular matrix modulation, a mechanism affected by hypoxia. The modulation of the extracellular matrix is important to facilitate tumour cell migration and enhances sarcoma metastasis as shown by [@bib9].

Our findings showing an upregulation of genes encoding proteins involved in the glycolysis, such as SLC2A1, PFKB3, ALDOA, and PDK1, could be explained by the metabolic switch from oxidative phosphorylation to glycolysis as a result of tumour cell hypoxia ([@bib28]). However, it is important to remember that these genes could also be upregulated in cancers for reasons unrelated to hypoxia. The prognostic impact of these glycolysis genes are in concordance with the data showing that the total tumour glycolysis estimated by FDG PET/CT in sarcoma patients is associated with metastatic disease ([@bib8]).

All the genes included in the profile are involved in the mechanisms that facilitate aggressive tumour behaviour such as metastasis and/or resistance to treatment ([@bib11]; [@bib6]; [@bib14]; [@bib37]). Therefore, this gene profile may be a generally applicable signature for hypoxic and/or aggressive tumours.

To the best of the authors\' knowledge, this is the second largest study of a prognostic gene profile in STS patients after the CINSARC profile ([@bib7]). Yet, because of the various histological subtypes, the number of patients in each histological subtype is still relatively small. This hinders any pathology-specific analysis of data.

The relative wide 95% CIs of the survival estimate means these are subject to some uncertainty. Furthermore, the lower HR for hypoxia in the validation cohort indicates a weaker relationship between DFS and the hypoxic gene signature, and confirms the importance of further validation of this gene signature in an independent cohort. This, however, does not affect the fact that the differences in disease-specific mortality, overall mortality, and development of metastasis were significant.

The development of metastasis was the secondary end point used in this study. This end point was defined as metastasis with no possibility of curative treatment. Specifying the palliative intent in the definition of the end point was based on the assumption that tumours that develop solitary or oligometastasis that could be treated curatively may have a different and less aggressive biology compared with tumours that develop widespread systemic disease.

Intra-tumour heterogeneity is a well-known issue in regards to the extent of hypoxia ([@bib17]), and this is a concern for biomarker studies based on single tumour biopsies. For the hypoxia signature, this question has been raised in a previous study ([@bib35]), where intra-tumour heterogeneity was tested in multiple biopsies with different tumour tissue content from individual head and neck cancer patients. It was found that for the majority of patients, all biopsies from the same patient were classified the same. The conclusion from this study was, that if multiple biopsies are available, the optimal biopsy is selected by taking the relative content of invasive carcinoma, minimal necrosis, and the total size of the tumour biopsy into account. We have in this study performed a similar validation as described in Material and Methods and most patients were classified in the same groups used two different tissue samples.

A major strength of the present study is that the cut-point (ΔCq-value) determined by the test cohort for each gene was applied to the validation cohort independent of the patient\'s outcome. The data shown by Sorensen *et al* indicated that this hypoxia-induced gene profile may be universal for cancer, whereas our data indicated that different cancers may have different cut-points for each gene as the cut-points found in this study were indeed different from those found by Toustrup *et al.* This study also suggests that even various histological types of sarcomas may have different cut-points.

Other points of strength in this study are as follows: the strong correlation between tissue samples taken from the same patient, who testified for the robustness of the data, and the significant association between disease-specific survival and the hypoxia-induced gene profile, shown by using the bootstrapping method on the pooled data.

Data for this study were collected from a comprehensive newly validated sarcoma database covering all sarcoma patients in a well-defined geographic part of Denmark ([@bib22]). In the present study, we adjusted for confounders, which are known to affect overall survival of STS; even so, we observed a highly significant association between the hypoxia-induced gene profile and disease-specific mortality. Another important point is that the proposed analysis using FFPE tissue samples to evaluate the expression level of the hypoxia-induced gene profile can be used in clinical practice.

In the present study, there was no association between the hypoxia-induced gene expression and the Eppendorf oxygen tension measurements in a small group of 16 patients with high-grade sarcoma. This could simply be owing to the small number of patients with data available on tumour oxygen tension status.

Another possible explanation could be that pO~2~ measurements with the Eppendorf method could have been affected by, for example, tumour size or the degree of necrosis within a tumour. Previous clinical data in STS showed no such association, neither between tumour pO~2~ or tumour necrosis or size, respectively ([@bib27]). Preclinical studies using mouse models have collectively shown that the larger the tumour, the higher was the degree of necrosis and the lower was the oxygen tension inside the tumour ([@bib38]; [@bib19]; [@bib24]).

In this study, only a week correlation between tumour size and oxygen tension measurements was observed ([Supplementary Figure IIB](#sup1){ref-type="supplementary-material"}). This weak correlation can therefore cast a shadow of doubt on whether these genes in sarcomas are driven by hypoxia directly and not by other hypoxia-independent signalling pathways.

Indeed, our results cannot answer the question of whether these genes in sarcomas are driven by hypoxia or by other signalling pathways that are totally or partly independent of hypoxia. The distinction is important for understanding the underlying mechanism and determining the predictive value of this profile. As the current study was not designed to make this distinction, this point will be investigated in future studies testing the predictive role of this profile in determining the response to anti-hypoxic drugs alone or in combination with chemotherapy.

Determining tumour hypoxia using panel of genes, referred to as Hypoxia Gene Expression Signatures is now a commonly used strategy ([@bib34]; [@bib15]; [@bib29]) This is due to the advantages of using a cumulated gene response to hypoxia, instead of focusing on a single biomarker. Previously, immunohistochemistry (IHC) using single markers has been used in number of clinical studies, but because of the number of disadvantages of this method ([@bib15]) it was not used here. It was also felt treat the use of IHC would not add more information to the results particularly that the correlation between the expression of the hypoxia inducible genes included in the 15-gene hypoxia-induced gene profile and tumour hypoxia has been validated in a preclinical study, with tumour hypoxia being assessed by FAZA, an exogenous hypoxia marker ([@bib36]).

In conclusion, the results of the present paper suggest a new hypoxia-induce gene profile prognostic for STS patients.
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![Diagram of patient selection of test and validation cohort. ARS=Aarhus sarcoma registry; OTM=oxygen tension measurement; STS=soft tissue sarcoma. \*Nordsmark et al. British Journal of Cancer, 2001 and Bentzen *et al.* Radiotherapy and Oncology, 2003.](bjc2016310f1){#fig1}

![Disease-specific and overall mortality for the test and validation cohort. (**A**) Heat map visualising gene expression in the test cohort of 55 STS tissue samples (1--55), red is upregulated genes, green is downregulated genes, and grey is missing values (expression levels below the detection threshold).\
All gene expression levels are median centred. (**B**) Disease-specific mortality in the test cohort. (**C**) Overall mortality in test cohort. Less hypoxic: patients allocated to the less hypoxic group with low expression of the hypoxia-induced genes. More hypoxic: patients allocated to the more hypoxic group with high gene expression of the hypoxia-induced genes. The values are unadjusted and based on Fine and Gray competing risk model. (**D**) Heat map visualising gene expression from the validation cohort of 77 STS tissue samples (1--77). (**E**) Disease-specific mortality in the validation cohort. (**F**) Overall mortality in the validation cohort.](bjc2016310f2){#fig2}

###### Patient, tumour, and treatment characteristics of patient treated for high-grade localised soft tissue sarcoma (*n*=132)

                                     **Total**      **Test cohort**   **Validation cohort**  ***P*****-value**[a](#t1-fn1){ref-type="fn"}
  ---------------------------------- ------------- ----------------- ----------------------- ----------------------------------------------
  Total                                                   55                   77             
  Age at diagnosis (years)                                                                    
   Median (range)                    60 (17--88)      54 (23--88)          61 (17--83)       0.65
  Sex                                                                                         
   Female                            49 (37)            19 (35)              30 (39)          
   Male                              83 (63)            36 (65)              47 (61)         0.61
  Comorbidity                                                                                 
   No                                106 (80)           48 (87)              58 (75)          
   Yes                               26 (19)            7 (13)               19 (25)         0.12
  Tumour size (cm)                                                                            
   Median (range)                    9 (2--26)         9 (2--26)            8 (2--23)        0.98
  Site                                                                                        
   Axial/pelvis                      16 (12)            8 (15)               8 (10)           
   Extremities                       116 (88)           47 (85)              69 (90)         0.59
  Histology                                                                                   
   Liposarcoma                       28 (21)            14 (25)              14 (18)          
   UPS                               51 (39)            19 (35)              32 (42)          
   Synovial sarcoma                  14 (10)             3 (5)               11 (14)          
   Others                            39 (30)            19 (35)              20 (26)         0.23
  Grade                                                                                       
   II                                12 (9)                0                 12 (16)          
   III                               119 (91)          55 (100)              64 (84)         \< 0.01
  Depth[b](#t1-fn2){ref-type="fn"}                                                            
   Subcutis                          6 (5)              6 (11)                  0             
   Deep                              124 (94)           47 (85)             77 (100)         \<0.01
  Margin                                                                                      
   Wide                              78 (60)            41 (75)              37 (48)          
   Intralesional/marginal            54 (41)            14 (25)              40 (52)         0.002
  Radiation                                                                                   
   Yes                               108 (82)           31 (56)             77 (100)          
   No                                24 (18)            24 (44)                 0             
  Recurrence                                                                                  
   Yes                               65 (49)            25 (45)              40 (52)          
   No                                67 (51)            30 (55)              37 (48)         0.46

Abbreviation: UPS=undifferentiated pleomorphic sarcoma.

The values are numbers (%).

*P*-value: Fisher\'s exact test or *χ*^2^-test, and Wilcoxon rank-sum test.

No superficial tumours, two missing values.

###### Distribution of patients with both oxygen tension measurements and gene expression analysis (*n*=16)

                         **Oxygen tension measurements**  
  --------------------- --------------------------------- ---
  High (more hypoxic)                   2                  9
  Low (less hypoxic)                    4                  1

Fisher\'s exact test=0.036.

###### Patient, tumour, and treatment characteristics of the pooled STS patients with localised high-grad soft tissue sarcoma (*n*=110)

                               **Total**    **More hypoxic**   **Less hypoxic**   ***P*****-value**[a](#t3-fn1){ref-type="fn"}
  -------------------------- ------------- ------------------ ------------------ ----------------------------------------------
  Total                                            55                 55                                
  Age at diagnosis (years)                                                                              
   Median (range)             61 (24--83)     64 (36--83)        54 (24--81)                         \<0.01
  Sex                                                                                                   
   Female                       42 (38)         18 (33)            24 (44)                              
   Male                         68 (62)         37 (67)            31 (56)                            0.24
  Comorbidity                                                                                           
   No                           87 (79)         41 (75)            46 (84)                              
   Yes                          23 (21)         14 (25)             9 (16)                            0.35
  Tumour size (cm)                                                                                      
   Median (range)              9 (2--26)       10 (2--26)         9 (2--20)                           0.25
  Site                                                                                                  
   Axial/pelvis                 12 (11)          6 (11)             6 (11)                              
   Extremities                  98 (89)         49 (89)            49 (89)                             1
  Histology                                                                                             
   Liposarcoma                  22 (20)         11 (20)            11 (20)                           \<0.01
   UPS                          43 (39)         23 (42)            20 (36)                              
   Synovial sarcoma             14 (13)            0               14 (13)                              
   Others                       31 (28)         21 (38)            10 (18)                              
  Margin                                                                                                
   Wide                         62 (56)         28 (51)            34 (62)                              
   Intralesional/marginal       48 (44)         27 (49)            21 (38)                            0.25
  Radiation                                                                                             
   Yes                          93 (85)         44 (80)            49 (89)                              
   No                           17 (15)         11 (20)             6 (11)                            0.29
  Develops metastasis                                                                                   
   Yes                          55 (50)         30 (55)            25 (45)                              
   No                           55 (50)         25 (45)            30 (55)                            0.34

Abbreviation: UPS=undifferentiated pleomorphic sarcoma.

The values are numbers (%). Patients with superficial or grade 2 tumours are excluded from this analyses.

*P*-value: Fisher\'s exact test or *χ*^2^-test and Wilcoxon rank-sum test.

###### Multivariate analysis pooling the test cohort and validation cohort

                             **Overall mortality**            **Disease specific mortality**                                
  -------------------- ---- ----------------------- -------------------------------------------------- -------------------- --------------------------------------------------
  Age (year)                 ***1.0 (1.0; 1.1)***                  ***1.0 (1.0; 1.1)***                   1.0 (1.0; 1.0)                      1.0 (1.0; 1.0)
  Sex                                                                                                                                                
   Female               42             1                                                                        1                                    
   Male                 68      1.3 (0.8; 2.1)                                                            1.3 (0.7; 2.4)                             
  Comorbidity                                                                                                                                        
   No                   87             1                                    1                                   1                                   1
   Yes                  23      1.7 (1.0; 3.0)                        1.5 (0.8; 2.8)                      1.5 (0.7; 3.1)                      1.4 (0.7; 2.99
  Size (cm)                  ***1.1 (1.0; 1.1)***                  ***1.1 (1.0; 1.2)***                   1.0 (1.0; 1.1)                      1.1 (1.0; 1.2)
  Site                                                                                                                                               
   Axial/pelvis/head    12             1                                    1                                   1                                   1
   Extremities          98      0.5 (0.3; 1.0)                     ***0.4 (0.2; 0.9)***                   0.6 (0.3; 1.5)                      0.6 (0.3; 1.6)
  Hypoxic                                                                                                                                            
   Less                 55             1                                    1                                   1                                   1
   More                 55   ***2.2 (1.3; 3.6)***                  ***2.5 (1.4; 4.7)***                 **2.2 (1.2; 3.9)**                 ***3.2 (1.5; 7.0)***
  Histology                                                                                                                                          
   UPS                  43             1                                                                        1                                    
   Liposaroma           22      1.3 (0.7; 2.4)                                                            1.5 (0.6; 3.5)                             
   Synovial sarcoma     14      1.3 (0.6; 2.6)       ***4.7 (1.9; 11.6)***[b](#t4-fn2){ref-type="fn"}     1.4 (0.7; 3.0)     ***4.1 (1.4; 11.9)***[b](#t4-fn2){ref-type="fn"}
   Others               31      0.9 (0.5; 1.7)                                                            1.9 (0.8; 4.5)                             
  Margin                                                                                                                                             
   Wide                 62             1                                    1                                   1                                   1
   Non-wide             48      1.3 (0.8; 2.1)                        0.9 (0.5; 1.5)                      1.5 (0.8; 2.7)                      1.2 (0.6; 2.3)
  Radiation                                                                                                                                          
   No                   17             1                                                                        1                                    
   Yes                  93      0.8 (0.4; 1.6)                                                            0.9 (0.4; 2.7)                             

Abbreviations: CI=confidence interval; HR=hazard ratio; UPS=undifferentiated pleomorphic sarcoma.

Number of events analysing overall mortality was 66.

Number of events analysing disease specific mortality was 44.

Crude and adjusted analysis of potential prognostic factor for overall and disease-specific mortality for patient with localised high-grade disease and treated with surgery (***n***=110). Superficial and grade 2 tumours were excluded. The Bold and italic entries are the significant results.

Adjustments were made for tumour size, histology, margin, age, site, and comorbidity.

The histological types were group into synovial sarcoma ***vs*** all other histological types.
